Vancouver-based Numinus Wellness operates as a mental health and wellness company creating ecosystems of solutions around psychedelic-assisted psychotherapy. The company is focused on three areas: 1) Health–psychedelic therapy clinics, 2) Research and development (R&D)–supporting pharma companies to host studies, develop medical and therapeutic protocols, and influence regulatory approval for psychedelic clinical trials, and 3) Bioscience–testing, selling, and distributing psychedelic substances. 

Numinus has been expanding its clinical network through a series of acquisitions. It operates a total of 13 clinics, as of June 2022, which offer ketamine-assisted psychotherapy, special access to psilocybin and MDMA (pending approval by Health Canada), and compassionate access trials for psilocybin and MDMA. In June 2022, eight clinics were added to its network via the acquisition of fellow psychedelic company Novamind . In July 2021, the company announced the acquisition of the Neurology Centre of Toronto (NCT) to set up a Centre for Psychedelic Neurology and acquired a pair of Montreal clinics from Quebec-based psychedelic company Mindspace in December 2020. 

The company operates a 7,000 sq ft research and testing laboratory center and, through its subsidiary, Salvation Labs, maintains a Dealer’s Licence issued by Health Canada, to possess, buy, and sell MDMA, psilocybin, psilocin, DMT, and mescaline. 

In October 2020, Numinus became the first company to complete the legal harvest of magic mushrooms in Canada for research and development purposes. The company is traded on the TSX Venture Exchanges under the symbol NUMI.